1500

PAGE: 1

44

Maliszewski, C R.

RAW SEQUENCE LISTING

PATENT APPLICATION US/09/454,223

DATE: 12/27/1999 TIME: 12:42:18

Input Set: I454223.RAW

This Raw Listing contains the General Information
Section and up to first 5 pages.

```
1
     <110> APPLICANT: Kornbluth, Richard S
     <120> TITLE OF INVENTION: Multimeric forms of CD40L and other TNF family members
 3
     <130> FILE REFERENCE: TNFSF-collectin fusion proteins
     <140> CURRENT APPLICATION NUMBER: US/09/454,223
 5
     <141> CURRENT FILING DATE: 1999-12-09
 6
     <160> NUMBER OF SEQ ID NOS: 6
 7
     <170> SOFTWARE: PatentIn Ver. 2.1
 8
     <210> SEQ ID NO 1
 9
     <211> LENGTH: 1552
     <212> TYPE: DNA
10
     <213> ORGANISM: Artificial Sequence
11
12
     <220> FEATURE:
     <221> NAME/KEY: 5'UTR
13
14
     <222> LOCATION: (7)..(31)
     <220> FEATURE:
15
16
     <221> NAME/KEY: misc feature
17
     <222> LOCATION: (88)..(799)
     <223> OTHER INFORMATION: Mature murine surfactant protein D including hub
18
19
           region, collagenous portion, and neck, but
20
           excluding carbohydrate recognition domain (CRD)
21
     <220> FEATURE:
     <221> NAME/KEY: misc feature
22
23
     <222> LOCATION: (801)..(1546)
24
     <223> OTHER INFORMATION: Human CD40 ligand extracellular region, including
           stalk.
25
     <220> FEATURE:
26
     <221> NAME/KEY: sig_peptide
28
     <222> LOCATION: (32)..(88)
     <223> OTHER INFORMATION: Signal peptide from murine surfactant protein D
30
     <220> FEATURE:
31 <221> NAME/KEY: CDS
     <222> LOCATION: (32)..(1444)
32
33
     <220> FEATURE:
     <223> OTHER INFORMATION: Description of Artificial Sequence: Murine
35
           surfactant protein D (without the CRD) fused to
36
           the extracellular portion of human CD40L
37
     <300> PUBLICATION INFORMATION:
38
     <301> AUTHORS: Spriggs, Melanie K.
39
           Armitage, Richard J.
40
           Strockbine, L
41
           Clifford, K N.
42
           Macduff, B M.
43
           Sato, T.A.
```

PAGE: 2 RAW SEQUENCE LISTING DATE: 12/27/1999

PATENT APPLICATION US/09/454,223 TIME: 12:42:18

```
45
           Fanslow, William C.
46
     <302> TITLE: Recombinant human CD40 ligand stimulates B cell
           proliferation and immunoglobulin E secretion.
47
     <303> JOURNAL: J. Exp. Med.
48
     <304> VOLUME: 176
49
50
     <305> ISSUE: 6
51
     <306> PAGES: 1543-1550
     <307> DATE: 1992
52
53
     <313> RELEVANT RESIDUES: 801 TO 1600
     <300> PUBLICATION INFORMATION:
54
     <301> AUTHORS: Motwani, M
56
     <302> TITLE: Mouse surfactant protein-D.
                                               cDNA cloning,
     <303> JOURNAL: J. Immunol.
57
     <304> VOLUME: 155
58
     <305> ISSUE: 12
59
     <306> PAGES: 5671-5677
60
61
     <307> DATE: 1995
     <313> RELEVANT RESIDUES: 32 TO 800
62
63
     <400> SEQUENCE: 1
                                                                                52
           gctagcgaat tccaccagga agcaatctga c atg ctg ccc ttt ctc tcc atg
64
                                               Met Leu Pro Phe Leu Ser Met
65
66
           ctt gtc ttg ctt gta cag ccc ctg gga aat ctg gga gca gaa atg aag
                                                                                100
67
           Leu Val Leu Leu Val Gln Pro Leu Gly Asn Leu Gly Ala Glu Met Lys
68
69
                    10
                                         15
70
           age etc teg cag aga tea gta ecc aac acc tge acc eta gte atg tgt
                                                                                148
           Ser Leu Ser Gln Arg Ser Val Pro Asn Thr Cys Thr Leu Val Met Cys
71
                                     30
72
                                                                                196 ·
73
           age eca aca gag aat gge etg eet ggt egt gat gga egg gat ggg aga
           Ser Pro Thr Glu Asn Gly Leu Pro Gly Arg Asp Gly Arg Asp Gly Arg
74
75
76
           gaa ggt cca cgg ggt gag aag ggt gat cca ggt ttg cca gga cct atg
                                                                                244
           Glu Gly Pro Arg Gly Glu Lys Gly Asp Pro Gly Leu Pro Gly Pro Met
77
78
                             60
                                                 65
79
           ggg ctc tca ggg ttg cag ggc cct aca ggt cca gtt gga ccc aaa gga
                                                                                292
80
           Gly Leu Ser Gly Leu Gln Gly Pro Thr Gly Pro Val Gly Pro Lys Gly
81
                        75
                                             80
82
           gag aat ggc tct gct ggc gaa cct gga cca aag gga gaa cgt gga cta
                                                                                340
83
           Glu Asn Gly Ser Ala Gly Glu Pro Gly Pro Lys Gly Glu Arg Gly Leu
84
                                         95
85
           agt gga cet cea gga ett cea ggt att cet ggt cea get ggg aaa gaa
                                                                                388
           Ser Gly Pro Pro Gly Leu Pro Gly Ile Pro Gly Pro Ala Gly Lys Glu
86
87
                                    110
           ggt ccc tct ggg aag cag ggg aac ata gga cct caa ggc aaa cca ggt
                                                                                436
88
           Gly Pro Ser Gly Lys Gln Gly Asn Ile Gly Pro Gln Gly Lys Pro Gly
89
                                                    130
                                                                          135
90
           120
                                125
           cct aaa gga gag gct ggg ccc aaa gga gaa gta ggt gct cct ggc atg
                                                                                484
91
           Pro Lys Gly Glu Ala Gly Pro Lys Gly Glu Val Gly Ala Pro Gly Met
92
93
                                                145
           caa gga tot aca ggg gca aaa ggc toc aca ggc coc aag gga gaa aga
                                                                                532
94
```

RAW SEQUENCE LISTING DATE: 12/27/1999 TIME: 12:42:18 PAGE: 3

PATENT APPLICATION US/09/454,223

0.5	g1-	0 1	0	mb	a 1	21.	T	~1	C	mb w	<i>-</i> 21	Dwa	T	~1··	Cli	7~~	
95 96	GIN	GIÀ	ser	155	GIY	Ald	гуѕ	GIY	160	THE	Gly	PIO	րչթ	165	GIU	Arg	
97	aat.	gcc	cct		ata	caa	σσа	σcc		aaa	aat	act	σσα		σca	gga	580
98		_						_			Asn	-	-				
99	2		170	3			2	175					180			•	
100	cct	qcc	qqa	cct	gcc	ggt	cca	cag	gga	gct	cca	ggt	tcc	agg	ggg	ccc	628
101		_			_			_		_	Pro						
102		185	-			•	190		-			195		_	_		
103	cca	gga	ctc	aag	ggg	gac	aga	ggt	gtt	cct	gga	gac	aga	gga	atc	aaa	676
104	Pro	Gly	Leu	Lys	Gly	Asp	Arg	Gly	Val	Pro	Gly	Asp	Arg	Gly	Ile	Lys	
105	200					205					210					215	
106	ggt	gaa	agc	ggg	ctt	cca	gac	agt	gct	gct	ctg	agg	cag	cag	atg	gag	724
107	Gly	Glu	Ser	Gly	Leu	Pro	Asp	Ser	Ala	Ala	Leu	Arg	Gln	${\tt Gln}$	Met	Glu	
108					220					225					230		
109	gcc	tta	aaa	gga	aaa	cta	cag	cgt	cta	gag	gtt	gcc	ttc	tcc	cac	tat	772
110	Ala	Leu	Lys	Gly	Lys	Leu	Gln	Arg	Leu	Glu	Val	Ala	Phe		His	Tyr	
111				235					240					245			
112			_	_	_						aga						820
113	Gln	Lys	Ala	Ala	Leu	Phe	Pro	_	Gly	His	Arg	Arg		Asp	Lys	Ile	
114			250					255					260				
115	_	_	_					-	_		gta		_				868
116	Glu	-	Glu	Arg	Asn	Leu		Glu	Asp	Phe	Val		Met	Lys	Thr	Ile	
117		265					270					275					
118											tcc						916
119		Arg	Cys	Asn	Thr	_	GIU	Arg	ser	ьеи	Ser	Leu	ьеи	Asn	сув		
120	280					285					290					295	064
121				_	_		_				aag	-					964
122	GIU	тте	гÀа	ser		Pne	GIU	GIY	Pne		Lys	Asp	тте	Met	310	ASII	
123					300		~~~	224	200	305	gaa	250	a aa	222		ast.	1012
124											Glu						1012
125 126	гур	GIU	GIU	315	пув	пуэ	GIU	ASII	320	FIIC	GIU	MEC	GIII	325	Gry	vob	
127	cad	aat	cct		att	aca	aca	cat		ata	agt	gag	acc		agt.	aaa	1060
128	_						_		-		Ser		_	-			
129	GIN	ADU	330	0111	-1-0	niu		335	•		701		340			_,,	
130	aca	aca		ata	tta	cag	taa		σaa	aaa	gga	tac		acc	atq	agc	1108
131											Gly						
132		345					350			•	•	355	•				
133	aac		ttq	qta	acc	ctq	qaa	aat	qqq	aaa	cag	ctq	acc	gtt	aaa	aga	1156
134			-								Gln						
135	360					365			_	•	370				-	375	
136	caa	gga	ctc	tat	tat	atc	tat	gcc	caa	gtc	acc	ttc	tgt	tcc	aat	cgg	1204
137											Thr						
138		_		-	380		_			385					390		
139	gaa	gct	tcg	agt	caa	gct	cca	ttt	ata	gcc	agc	ctc	tgc	cta	aag	tcc	1252
140	Glu	Ala	Ser	Ser	Gln	Ala	Pro	Phe	Ile	Ala	Ser	Leu	Cys	Leu	Lys	Ser	
141				395					400					405			
142											gct						1300
143	Pro	Gly	Arg	Phe	Glu	Arg	Ile	Leu	Leu	Arg	Ala	Ala		Thr	His	Ser	
144			410					415					420				

PAGE: 4 RAW SEQUENCE LISTING DATE: 12/27/1999

PATENT APPLICATION US/09/454,223 TIME: 12:42:18

145			_			_						cac	_			-		1348
146		Ser		_	Pro	Cys	Gly		Gln	Ser	Ile	His		Gly	Gly	Val	Phe	
147			425					430					435					
148		_	_				-	_			_	aat			_		_	1396
149		Glu	Leu	Gln	Pro	Gly	Ala	Ser	Val	Phe	Val	Asn	Val	Thr	Asp	Pro	Ser	
150		440					445					450					455	
151				_						_		ttt						1444
152		Gln	Val	Ser	His	Gly	Thr	Gly	Phe	Thr	Ser	Phe	Gly	Leu	Leu	Lys	Leu	
153						460					465					470		
154		tga	acag	tgt (cacc	ttgc	ag ge	ctgt	ggtg	g ag	ctga	cgct	ggg	agtc	ttc a	ataa	tacagc	1504
155		aca	ggct	taa 🤉	gccc	aatta	at a	cact	ccaa	g gc	atgt	agaa	ctg	gtac	C			1552
156	<210>	SEQ	ID :	NO 2														
157	<211>	11> LENGTH: 471																
158	<212>	212> TYPE: PRT																
159	<213>	<213> ORGANISM: Artificial Sequence																
160	<220>	<220> FEATURE:																
161	<223> OTHER INFORMATION: Description of Artificial Sequence: Murine																	
162	surfactant protein D (without the CRD) fused to																	
163	the extracellular portion of human CD40L																	
164	<400>	SEQ	JENC	E: 2														
165		Met	Leu	Pro	Phe	Leu	Ser	Met	Leu	Val	Leu	Leu	Val	Gln	Pro	Leu	Gly	
166		1				5					10					15	_	
167		Asn	Leu	Gly	Ala	Glu	Met	Lys	Ser	Leu	Ser	Gln	Arg	Ser	Val	Pro	Asn	
168					20			_		25			_		30			
169		Thr	Cys	Thr	Leu	Val	Met	Cys	Ser	Pro	Thr	Glu	Asn	Gly	Leu	Pro	Gly	
170			•	35				-	40					45			-	
171		Arq	Asp	Gly	Arq	Asp	Gly	Arq	Glu	Gly	Pro	Arg	Gly	Glu	Lys	Gly	Asp	
172		_	50	•	_	_	_	55		-		_	60		-	•	-	
173		Pro	Gly	Leu	Pro	Gly	Pro	Met	Gly	Leu	Ser	Gly	Leu	Gln	Gly	Pro	Thr	
174		65	-			-	70		•			75			•		80	
175		Gly	Pro	Val	Gly	Pro	Lys	Gly	Glu	Asn	Gly	Ser	Ala	Gly	Glu	Pro	Gly	
176		•			•	85	•	•			90			•		95	-	
177		Pro	Lys	Gly	Glu	Arg	Gly	Leu	Ser	Gly	Pro	Pro	Gly	Leu	Pro	Gly	Ile	
178			-	•	100	-	•			105			•		110	-		
179		Pro	Gly	Pro	Ala	Gly	Lys	Glu	Gly	Pro	Ser	Gly	Lys	Gln	Gly	Asn	Ile	
180			•	115		•	•		120			•	-	125	-			
181		Gly	Pro	Gln	Gly	Lys	Pro	Gly	Pro	Lys	Gly	Glu	Ala	Gly	Pro	Lys	Gly	
182		•	130		•	•		135		•	•		140	•		•	•	
183		Glu	Val	Gly	Ala	Pro	Gly	Met	Gln	Gly	Ser	Thr	Gly	Ala	Lys	Gly	Ser	
184		145		•			150			•		155	•		-	•	160	
185			Gly	Pro	Lys	Gly	Glu	Arq	Gly	Ala	Pro	Gly	Val	Gln	Gly	Ala	Pro	
186			4			165		- 3	- 4		170	- 4			3	175		
187		Glv	Asn	Ala	Glv		Ala	Glv	Pro	Ala		Pro	Ala	Glv	Pro		Gly	
188		- 4			180			- 4		185	- 4			4	190		-	
189		Ala	Pro	Glv		Ara	Glv	Pro	Pro		Leu	Lys	Glv	Asp		Glv	Val	
190				195					200	1		-3-	1	205	3	1		
191		Pro	Glv		Ara	Glv	Ile	Lys		Glu	Ser	Gly	Leu		Asp	Ser	Ala	
192			210	F				215	2				220		F			
193		Ala		Arq	Gln	Gln	Met		Ala	Leu	Lys	Gly		Leu	Gln	Ara	Leu	
194		225					230					235					240	
-							-											

DATE: 12/27/1999 TIME: 12:42:18 RAW SEQUENCE LISTING PAGE: 5

PATENT APPLICATION US/09/454,223

														_				
195		Glu	Val	Ala	Phe		His	Tyr	Gln	Lys		Ala	Leu	Phe	Pro	_	Gly	
196						245					250					255		
197		His	Arg	Arg	Leu	Asp	Lys	Ile	Glu	Asp	Glu	Arg	Asn	Leu	His	Glu	Asp	
198					260					265					270			
199		Phe	Val	Phe	Met	Lys	Thr	Ile	Gln	Arg	Cys	Asn	Thr	Gly	Glu	Arg	Ser	
200				275					280					285				
201		Leu	Ser	Leu	Leu	Asn	Cys	Glu	Glu	Ile	Lys	Ser	Gln	Phe	Glu	Gly	Phe	
202			290					295					300					
203		Val	Lys	Asp	Ile	Met	Leu	Asn	Lys	Glu	Glu	Thr	Lys	Lys	Glu	Asn	Ser	
204		305	_	_			310					315					320	
205		Phe	Glu	Met	Gln	Lys	Gly	Asp	Gln	Asn	Pro	Gln	Ile	Ala	Ala	His	Val	
206						325					330					335		
207		Ile	Ser	Glu	Ala	Ser	Ser	Lys	Thr	Thr	Ser	Val	Leu	Gln	Trp	Ala	Glu	
208					340			_		345					350			
209		Lys	Gly	Tyr	Tyr	Thr	Met	Ser	Asn	Asn	Leu	Val	Thr	Leu	Glu	Asn	Gly	
210		_	_	355	_				360					365				
211		Lys	Gln	Leu	Thr	Val	Lys	Arg	Gln	Gly	Leu	Tyr	Tyr	Ile	Tyr	Ala	Gln	
212		_	370					375					380					
213		Val	Thr	Phe	Cys	Ser	Asn	Arg	Glu	Ala	Ser	Ser	Gln	Ala	Pro	Phe	Ile	
214		385					390					395					400	
215		Ala	Ser	Leu	Cys	Leu	Lys	Ser	Pro	Gly	Arg	Phe	Glu	Arg	Ile	Leu	Leu	
216						405					410					415		
217		Arg	Ala	Ala	Asn	Thr	His	Ser	Ser	Ala	Lys	Pro	Cys	Gly	${\tt Gln}$	${\tt Gln}$	Ser	
218					420					425					430			
219		Ile	His	Leu	Gly	Gly	Val	Phe	Glu	Leu	${\tt Gln}$	Pro	Gly	Ala	Ser	Val	Phe	
220				435					440					445				
221		Val	Asn	Val	Thr	Asp	Pro	Ser	${\tt Gln}$	Val	Ser	His	Gly	Thr	Gly	Phe	Thr	
222			450					455					460					
223		Ser	Phe	Gly	Leu	Leu	Lys	Leu										
224		465					470											
225	<210>	SEQ	ID 1	10 3														
226	<211>	LEN	GTH:	1574	<u>l</u>													
227	<212>	TYPE	E: Di	AV														
228	<213>	ORG	ANISM	tA : P	ctifi	cial	l Sec	quen	ce									
229	<220>	FEA?	TURE:	:														
230	<221>		•															
231	<222>																	
232	<223>	OTHE	ER IN	NFORI	MTIC	ON: 5	יטי פ	rr ta	aken	from	n rat	sec	quenc	e fo	or si	ırfac	ctant	
233		prot	ein	D														
234	<220>																	
235	<221>	MAM	E/KEY	វ: នា	ig_pe	eptic	de											
236	<222>																	
237	<223>				MATIC	N: 5	Signa	al pe	ptic	le fr	om n	nurir	ne su	ırfac	ctant	pro	otein	D
238	<220>																	
239	<221>																	
240	<222>				32)	(153	34)											
241	<220>																	
242	<221>				_													
243	<222>																	
244	<223>	OTHE	ER IN	1FORI	IATIC	N: N	<i>f</i> urir	ie si	ırfac	tant	pro	oteir	ı D i	inclu	ıding	j huk	regi	on,

PAGE: 6

. . . .

VERIFICATION SUMMARY DATE: 12/27/1999
PATENT APPLICATION US/09/454,223 TIME: 12:42:18

Input Set: I454223.RAW

Original Text Line ? Error/Warning